Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q1 EPS of $0.20, $0.01 better than the analyst estimate of $0.19. Revenue for the quarter came in at $45.4 million versus the consensus estimate of $44.34 million.

Meridian Bioscience, Inc. reaffirmed FY2013 guidance.

For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.

Earnings